Shanghai Junshi Biosciences Co.Ltd(688180) ::第4世代EGFR阻害剤JS 113薬物臨床試験申請受付通知書取得

4月 1, 2022

Shanghai Junshi Biosciences Co.Ltd(688180) 公告、持株子会社蘇州君境生物医薬科学技術有限会社は国家薬品監督管理局が発行した「受理通知書」を受け取り、第4世代EFR阻害剤WJ 13404錠(プロジェクト番号「JS 113」)の臨床試験申請が受理された。

- Advertisment -

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

常に有効

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	期間	説明
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Functional

Performance

Analytics

Others

Shanghai Junshi Biosciences Co.Ltd(688180) ::第4世代EGFR阻害剤JS 113薬物臨床試験申請受付通知書取得

ゼロ・トレランス! 激しい規制措置! この2社は上場廃止になる可能性があります

ライトニング! 会社の実質的な所有者が行方不明! 証券会社会長の大事件に巻き込まれる可能性

トゥースマウ」の取締役会長が証券取引委員会に申請された：同社の時価総額は、かつて1000億円近くも蒸発したが、いつ栄光が戻るのか：

Kalite社：株式の新規公開とGEM上場のお知らせ

マトリックス：当社の株式新規公開およびGEM上場に関するGuoco法律事務所（深セン）の法律意見書について

維格科技：新規株式公開目論見書

維格科技：新規株式公開のお知らせ

Weigang Technology社：新規株式公開目論見書の概要

維格科技：株式公開に伴う投資リスクに関する特別措置のお知らせ

601136:資本証券による株式公開第一回投資リスクに関する特例公告について

601136:資本証券による新規株式公開の予備的見積もり結果及び延期に関するお知らせ